Journal of clinical lipidology · 2026
Symptom and comorbidity burden in familial chylomicronemia syndrome: Impact on quality of life.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aboheimed Ghada I, AlRasheed Maha M, Alfattani Areej A, Alhusayn Khalid O, Alali Shog M, Alkhbiah Reema A, Colak Dilek, Alashwal Abdullah, Kaya Namik
Аннотация
BACKGROUND: Familial chylomicronemia syndrome (FCS) is a severe, life-threatening genetic disorder resulting from pathogenic variants in genes involved in lipoprotein lipase (LPL) function, including LPL, APOC2, APOA5, GPIHBP1, and LMF1.
OBJECTIVE: This study aimed to assess the quality of life (QoL) of patients with FCS and explore the relationship between clinical symptoms, comorbidities, and QoL.
METHODS: The study was conducted over 12 months and involved genetically confirmed patients with FCS and healthy controls in Saudi Arabia. Data were collected using a structured questionnaire and the validated Arabic version of the PedsQL 4.0 Generic Core Scale. Statistical analyses included descriptive statistics, the Mann-Whitney U test for comparisons between patients with FCS and healthy controls, and Fisher's exact test for categorical variables. A P value of <.05 was considered statistically significant.
RESULTS: Twenty-eight patients with FCS and 142 controls participated. Commonly reported symptoms among patients with FCS included stomach bloating (25%), persistent stomach pain (21%), nausea (18%), xanthomas (21%), and anxiety related to pancreatitis (39%). Comorbidities such as chronic pancreatitis (29%), vision problems (18%), weakness (14%), and eating disorders (11%) were also observed. Patients with frequent stomach pain (P = .002), bloating (P = .016), and nausea (P = .044) were significantly more likely to have comorbidities. In addition, xanthomas (P = .038) and anxiety related to pancreatitis (P = .049) were more prevalent in patients with comorbidities. QoL was significantly lower in patients with FCS with comorbidities (median score 86) compared with those without (median 92, P = .019), particularly in the physical health domain (P = .006).
CONCLUSION: FCS significantly affects QoL, especially when comorbidities are present. Symptom burden, particularly gastrointestinal symptoms, is closely linked to comorbidities and poorer QoL. These findings highlight the need for symptom-focused care and early comorbidity management to improve patient outcomes.
OBJECTIVE: This study aimed to assess the quality of life (QoL) of patients with FCS and explore the relationship between clinical symptoms, comorbidities, and QoL.
METHODS: The study was conducted over 12 months and involved genetically confirmed patients with FCS and healthy controls in Saudi Arabia. Data were collected using a structured questionnaire and the validated Arabic version of the PedsQL 4.0 Generic Core Scale. Statistical analyses included descriptive statistics, the Mann-Whitney U test for comparisons between patients with FCS and healthy controls, and Fisher's exact test for categorical variables. A P value of <.05 was considered statistically significant.
RESULTS: Twenty-eight patients with FCS and 142 controls participated. Commonly reported symptoms among patients with FCS included stomach bloating (25%), persistent stomach pain (21%), nausea (18%), xanthomas (21%), and anxiety related to pancreatitis (39%). Comorbidities such as chronic pancreatitis (29%), vision problems (18%), weakness (14%), and eating disorders (11%) were also observed. Patients with frequent stomach pain (P = .002), bloating (P = .016), and nausea (P = .044) were significantly more likely to have comorbidities. In addition, xanthomas (P = .038) and anxiety related to pancreatitis (P = .049) were more prevalent in patients with comorbidities. QoL was significantly lower in patients with FCS with comorbidities (median score 86) compared with those without (median 92, P = .019), particularly in the physical health domain (P = .006).
CONCLUSION: FCS significantly affects QoL, especially when comorbidities are present. Symptom burden, particularly gastrointestinal symptoms, is closely linked to comorbidities and poorer QoL. These findings highlight the need for symptom-focused care and early comorbidity management to improve patient outcomes.